Work

A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings

Year: 2010

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v116.21.210.210

Authors: Jorge Cortes, Moshe Talpaz, Dale Bixby, Michael Deininger, Neil Shah, Ian W. Flinn, Michael Mauro, Thomas O'Hare, Simin Hu, Rebecca Kan, Victor M. Rivera, Tim Clackson, Frank Haluska, Hagop Kantarjian

Institutions: The University of Texas MD Anderson Cancer Center, University of Michigan, Oregon Health & Science University, University of California, San Francisco, Sarah Cannon, Howard Hughes Medical Institute, ARIAD Pharmaceuticals (United States)

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2979500475

FWCI: 10.06

Cites:

Cited by: 70

Related to: 10